Johnson & Johnson Phase 3 data released: one jab, 72% efficiency

by



[ad_1]

The third major alternative for a COVID-19 vaccine, Johnson & Johnson, released their Phase 3 interim analysis data on Friday. The vaccine name is ENSEMBLE.

ENSEMBLE, known to be a single dose vaccine, was shown to be effective in 72% of the 43,783 recipients who entered the phase 3 trials.

“Our goal has always been to create a simple and effective solution for as many people as possible and to have maximum impact to help end the pandemic,” said CEO Alex Gorsky.

Among the participants, there were 468 cases of symptomatic COVID-19. These people were examined 14 to 28 days after being injected.

“Don’t let the perfect get in the way of the good,” Kizzmekia Corbett, one of the vaccine developers for Moderna, tweeted Friday, encouraged by ENSEMBLE’s effectiveness percentages.

Data showed that, from day 14 and peaking 28 days after vaccination, recipients were 66% protected against moderate to severe complications of COVID-19, so that even if one were to catch the virus in within 28 days of receiving this vaccine, the effects would not be severe 66% of the time.

The announcement notes that “the ENSEMBLE study results include efficacy against new emerging strains of coronavirus, including some highly infectious variants found in the United States, Latin America and South Africa.”

The vaccine’s efficacy rate has dropped dramatically from the United States, where it was 72%, to 57% in South Africa, where a new variant was recently discovered, causing concern globally. Concerns over the spread of the South African strain have contributed to the recent closure of Ben-Gurion airport.

“The potential to dramatically reduce the burden of severe disease, by providing an effective and well-tolerated vaccine with a single vaccination, is a critical part of the global public health response,” said Paul Stoffels, Scientific Director of Johnson & Johnson.

In addition, Johnson & Johnson plans to apply for an Emergency Use Authorization (EUA), as have previous vaccine candidates – Pfizer and Moderna -.

According to the data, the vaccine is 85% effective overall in preventing serious complications that can lead to hospitalizations.

The company said it would follow up with trial participants for “up to two years.”



[ad_2]

Source link